Leukemia research最新文献

{"title":"Outcome of adolescents and young adult acute myeloid leukemia patients compared with middle-aged patients: A single centre retrospective experience","authors":"RuiQi Chen,&nbsp;Mohaned AlHumaid,&nbsp;Georgina Daher-Reyes,&nbsp;Eshetu G. Atenafu,&nbsp;Steven Chan,&nbsp;Vikas Gupta,&nbsp;Dawn Maze,&nbsp;Andre C. Schuh,&nbsp;Mark D. Minden,&nbsp;Karen Yee,&nbsp;Aaron D. Schimmer,&nbsp;Hassan Sibai","doi":"10.1016/j.leukres.2024.107586","DOIUrl":"10.1016/j.leukres.2024.107586","url":null,"abstract":"<div><div>Adult acute myeloid leukemia (AML) patients under the age of 60 often receive similar intensive treatments, while outcomes between the adolescent and young adult (AYA) age group (18−39) and middle-aged adults (40–60 years) were seldom reported. We aim to study the characteristics and outcomes of AYA patients in comparison to middle-aged adults. A retrospective analysis was performed on AYA patients treated at Princess Margaret Cancer Center between 2008 and 2018. The primary outcomes include overall survival (OS), cumulative incidence of relapse (CIR), and non-relapse mortality (NRM).</div><div>A total of 174 AYA patients and 176 middle-aged patients were included, with propensity score matching adjusting for potential major confounders. Comparing AYA and middle-aged patients, 5-year OS rates were similar at 54.6 % vs. 56.5 % (p=0.91), CIR rates at 29.5 % vs. 23.1 % (p=0.31), and similar NRM rates. Notably, non-transplanted AYA patients had a significantly higher CIR (39.8 %) compared to middle-aged patients (19.6 %) (p=0.0324), with more primary refractory/early relapsing disease. An observed trend toward improved OS in AYA patients post-2015 coincided with FLAG-IDA and haploidentical transplant implementations.</div><div>In conclusion, the study suggests that AYA patients, particularly those not undergoing transplantation, may benefit from more intensive treatment strategies, emphasizing the need for tailored approaches in this age group.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107586"},"PeriodicalIF":2.1,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the risk of venous thromboembolism and bleeding among patients with myeloproliferative neoplasms undergoing total knee and hip arthroplasty","authors":"Josue Marquez ,&nbsp;Samantha Simon ,&nbsp;Jeffrey I. Zwicker,&nbsp;Robert Flaumenhaft,&nbsp;Brian Hollenbeck,&nbsp;Rushad Patell","doi":"10.1016/j.leukres.2024.107591","DOIUrl":"10.1016/j.leukres.2024.107591","url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"146 ","pages":"Article 107591"},"PeriodicalIF":2.1,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142322721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-centric care in myelodysplastic syndromes: A global systematic literature review and gap analysis","authors":"Edward P. Armstrong ,&nbsp;Duska M. Franic ,&nbsp;Daniel C. Malone ,&nbsp;Patrick Mellors ,&nbsp;Sissi V. Pham ,&nbsp;Cristina Masseria ,&nbsp;Lorie Mody ,&nbsp;Cosmina Hogea","doi":"10.1016/j.leukres.2024.107592","DOIUrl":"10.1016/j.leukres.2024.107592","url":null,"abstract":"<div><h3>Background</h3><div>Disease progression and poor prognosis in higher-risk (HR) myelodysplastic syndrome (MDS) create an urgent need for interventions to improve the patient care experience in this vulnerable population. Patient-centric physician-supported strategies in conjunction with emerging therapies can help advance overall care and improve outcomes. The objective of this study was to evaluate patient-centric care (PCC) in the treatment of HR-MDS and identify opportunities to develop strategies to address care gaps for an optimal patient care experience.</div></div><div><h3>Methods</h3><div>A global systematic literature review (SLR) was conducted by cross-referencing MDS/HR-MDS with PCC terms, using PubMed, Embase, and Cochrane Collaboration databases (2017–2022) in accordance with Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines.</div></div><div><h3>Results</h3><div>In all, 59 MDS articles (45 empirical, 14 reviews) met the study inclusion criteria. Of these, 6 empirical articles focused on the HR-MDS population while none of the reviews did. Identified themes fell into 2 categories: health-related quality of life (HRQoL) and disparities. HRQoL was further categorized based on findings in the literature to include groupings of patient-reported outcomes (PROs), fatigue/frailty, and patient/preferences/treatment decisions/shared decision making (SDM).</div></div><div><h3>Conclusions</h3><div>With new treatments potentially on the horizon for HR-MDS, a call to action is timely to address the overall lack of empirical PCC data. The patient-centric approach presents critical opportunities for integration of physician-supported strategies with more effective first-line therapies to help optimize the journey of patients with HR-MDS and ensure meaningful outcomes by reducing patient/caregiver burden, aligning with and respecting patient preferences, and including patients as active participants in their treatment.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107592"},"PeriodicalIF":2.1,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142327730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of a predictive model for tumor lysis syndrome in childhood acute lymphoblastic leukemia","authors":"Yao Xiao ,&nbsp;Li Xiao ,&nbsp;Ximing Xu ,&nbsp;Xianmin Guan ,&nbsp;Yuxia Guo ,&nbsp;Yali Shen ,&nbsp;XiaoYing Lei ,&nbsp;Ying Dou ,&nbsp;Jie Yu","doi":"10.1016/j.leukres.2024.107587","DOIUrl":"10.1016/j.leukres.2024.107587","url":null,"abstract":"<div><h3>Background</h3><div>Tumor lysis syndrome (TLS) frequently manifests shortly after induction chemotherapy for acute lymphoblastic leukemia (ALL), with the potential for swift progression. This study endeavored to develop a nomogram to predict the risk of TLS, utilizing clinical indicators present at the time of ALL diagnosis.</div></div><div><h3>Methods</h3><div>We retrospectively gathered data from 2243 patients with ALL, spanning December 2008 to December 2021, utilizing the clinical research big data platform of the National Center for Clinical Research on Children's Health and Diseases. The Least Absolute Shrinkage and Selection Operator (LASSO) method was employed to filter variables and identify predictors, followed by the application of multivariate logistic regression to construct the nomogram.</div></div><div><h3>Results</h3><div>The LASSO regression identified six critical variables among ALL patients, upon which a nomogram was subsequently constructed. Multifactorial logistic regression revealed that an elevated white blood cell count (WBC), serum phosphorus &lt;2.1 mmol/L, potassium &lt;3.5 mmol/L, aspartate transaminase (AST) ≥50 U/L, uric acid (UA) ≥476μmol/L, and the presence of acute kidney injury (AKI) at the time of initial diagnosis were significant risk factors for the development of TLS in ALL patients (P&lt;0.05). The predictive model achieved an area under the receiver operating characteristic curve (AUC) of 0.824 [95 % CI (0.783, 0.865)], with an internal validation AUC of 0.859 [95 % CI (0.806, 0.912)]. The Hosmer-Lemeshow goodness-of-fit test confirmed the model’s robustness (P=0.687 for the training cohort; P=0.888 for the validation cohort). Decision curve analysis (DCA) indicated that the predictive model provided substantial clinical benefit across threshold probabilities ranging from 10 % to 70 %.</div></div><div><h3>Conclusions</h3><div>A nomogram incorporating six predictive variables holds significant potential for accurately forecasting TLS in pediatric patients with ALL.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"146 ","pages":"Article 107587"},"PeriodicalIF":2.1,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142312642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gene regulatory mechanisms of T cell exhaustion in diffuse large B cell lymphoma based on single-cell transcriptome data","authors":"Zhencang Zhou ,&nbsp;Pinwei Zhu ,&nbsp;Jinli Ge,&nbsp;Qiang Li,&nbsp;Hang Li,&nbsp;Nana Zhe,&nbsp;Zhaoyu Liu,&nbsp;Dengke Chen","doi":"10.1016/j.leukres.2024.107588","DOIUrl":"10.1016/j.leukres.2024.107588","url":null,"abstract":"<div><div>Diffuse large B cell lymphoma (DLBCL) is a heterogeneous and aggressive B cell malignancy that accounts for about 30 % of non-Hodgkin lymphomas. The current standard treatment for DLBCL is rituximab plus chemotherapy, but many patients are refractory or relapse, indicating the need for improved understanding of its molecular pathology. T cell exhaustion is a state of dysfunction or impairment that occurs in chronic infections or cancers, and is associated with poor prognosis in DLBCL. However, the molecular mechanisms of T cell exhaustion in DLBCL are poorly understood. In this study, we performed a comprehensive analysis of T cell exhaustion in DLBCL using public single-cell transcriptome data. We identified different subtypes of T cells and characterized their gene expression features. We found that DLBCL had a significantly higher proportion of exhausted T cells than normal tonsil, and that exhausted T cells had distinct gene expression signatures from non-exhausted T cells. These signatures included genes related to inhibitory receptors, cytokines, transcription factors and metabolic enzymes. We also found that ID3 gene was significantly upregulated in exhausted T cells in DLBCL, which may play a key role in T cell exhaustion. We constructed a protein-protein interaction network, identifying major hub proteins involved in T cell exhaustion or migration. We also performed KEGG and GO enrichment analysis for the differentially expressed genes between exhausted and non-exhausted T cells, and found important signaling pathways related to T cell exhaustion in DLBCL. Our results provide new insights into the molecular mechanisms underlying T cell exhaustion and offer novel therapeutic targets for this complex disease.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"146 ","pages":"Article 107588"},"PeriodicalIF":2.1,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142290398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Strategies to overcome splicing variants interference in mutational testing for BCR::ABL1 KD","authors":"Juliana Bulchi,&nbsp;Leandro Farias,&nbsp;Daniel Blajberg Schaffel,&nbsp;Bruna Sabioni,&nbsp;Telma França Padilha,&nbsp;Marianne Camile Silva de Sousa,&nbsp;Gustavo Trevizani Stelzer,&nbsp;Ilana Zalcberg,&nbsp;Luciana Mayumi Gutiyama","doi":"10.1016/j.leukres.2024.107594","DOIUrl":"10.1016/j.leukres.2024.107594","url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"146 ","pages":"Article 107594"},"PeriodicalIF":2.1,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142312643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Roles of noncoding RNAs in multiple myeloma","authors":"Ming Lei ,&nbsp;Juan Liang ,&nbsp;Kaiyun Guo ,&nbsp;Langui Tang ,&nbsp;Yuxing He ,&nbsp;Xuefeng Wu","doi":"10.1016/j.leukres.2024.107593","DOIUrl":"10.1016/j.leukres.2024.107593","url":null,"abstract":"<div><div>Noncoding RNAs (ncRNAs) constitute a class of nucleic acid molecules within cells that do not encode proteins but play important roles in regulating gene expression, maintaining cellular homeostasis, and mediating cell signaling. This class encompasses microRNAs (miRNAs), long noncoding RNAs (lncRNAs), transfer RNAs (tRNAs), circular RNAs (circRNAs), small interfering RNAs (siRNAs), and others. miRNAs are pivotal in the regulation of gene expression in hematologic malignancies. Aberrant expression of lncRNAs has been confirmed in cancerous tissues, implicating their involvement in carcinogenesis or tumor suppression processes. tRNAs may induce errors or disturbances in protein synthesis, thereby affecting normal cellular function and proliferation. Moreover, circRNAs influence disease progression in tumors by modulating the expression of relevant genes, and siRNAs can inhibit tumor cell proliferation, invasion, and metastasis while inducing apoptosis. This review will elucidate the biological functions of ncRNAs in multiple myeloma (MM) and explore their potential value as therapeutic targets.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"146 ","pages":"Article 107593"},"PeriodicalIF":2.1,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142290399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk factors and mortality associated with venous thromboembolism in the elderly US population with chronic lymphocytic leukemia","authors":"Ambarina S. Faiz ,&nbsp;Shuang Guo ,&nbsp;Ashwin Sridharan ,&nbsp;Yong Lin ,&nbsp;Claire S. Philipp","doi":"10.1016/j.leukres.2024.107585","DOIUrl":"10.1016/j.leukres.2024.107585","url":null,"abstract":"<div><h3>Background</h3><p>Venous thromboembolism (VTE) causes morbidity and mortality in cancer patients. The association of VTE with known risk factors in chronic lymphocytic leukemia (CLL) is not known.</p></div><div><h3>Objective</h3><p>To examine risk factors and mortality associated with VTE in White, Black, and Asian CLL patients.</p></div><div><h3>Methods</h3><p>The United States SEER-Medicare database (2000–2015) was used for CLL patients ≥ 65 years. Logistic regression was used to examine VTE risk factors and Cox proportional regression was used to evaluate the effect of VTE on mortality in White, Black, and Asian CLL patients.</p></div><div><h3>Results</h3><p>Among 34,075 CLL patients, VTE was diagnosed in 11.6 % of 31,395 White, 14.6 % of 2062 Black and 6.3 % of 618 Asian patients. Risk of having VTE was, OR_a = 1.2 (95 % CI, 1.0–1.4) for Black patients and OR_a = 0.5 (95 % CI, 0.4–0.7) for Asian patients compared to White patients. Anemia and heart failure were associated with VTE in all three racial cohorts and were the only risk factors in Asian patients. Other risk factors in White patients were the same as in the overall population, including hypertension, obesity, COPD, kidney disease, diabetes, hyperlipidemia, myocardial infarction, and chemotherapy. In Black patients, other risk factors were hypertension, and chemotherapy. Mortality was slightly higher with VTE in the overall population and in White patients.</p></div><div><h3>Conclusion</h3><p>There was difference in VTE risk factors in White, Black, and Asian patients. VTE was marginally associated with mortality in CLL patients. Our findings may help to identify patients at higher risk of VTE in racially diverse CLL populations.</p></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"146 ","pages":"Article 107585"},"PeriodicalIF":2.1,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0145212624001516/pdfft?md5=51d092e7cce9aeb3921a627202776d5e&pid=1-s2.0-S0145212624001516-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142162963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of patients with acute myeloid leukemia treated with intensive therapy after failure of venetoclax-inclusive, less-intensive therapy","authors":"Rohan K. Achar,&nbsp;Benjamin J. McCormick,&nbsp;Emily Dworkin,&nbsp;Emily M. Geramita,&nbsp;Annie Im,&nbsp;Anand A. Patel,&nbsp;Talha Badar,&nbsp;Rory M. Shallis","doi":"10.1016/j.leukres.2024.107577","DOIUrl":"10.1016/j.leukres.2024.107577","url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"146 ","pages":"Article 107577"},"PeriodicalIF":2.1,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142232415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between myeloid disorders and adult onset-inflammatory syndromes, successful treatment with JAK-inhibitors: Case series and literature review","authors":"Rahul Mishra ,&nbsp;Cassandra Calabrese ,&nbsp;Akriti G. Jain ,&nbsp;Abhay Singh","doi":"10.1016/j.leukres.2024.107584","DOIUrl":"10.1016/j.leukres.2024.107584","url":null,"abstract":"<div><p>Approximately one-third of patients with myeloid disorders like myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) exhibit inflammatory and autoimmune disorders (IADs). These IADs often include atypical and incomplete forms of common autoimmune conditions, and exhibit resistance to conventional immunosuppressive therapies. There is growing interest in molecular relationships between IADs and MDS/CMML to find potential targeted therapies. Recently, patients with somatic mutations in the <em>UBA1</em> gene were identified as having VEXAS syndrome. Herein, we present a concise case-series illustrating concurrent elderly-onset inflammatory manifestations and myeloid disorders (MDS, CMML, and idiopathic cytopenia of undetermined significance). These patients manifested inflammatory or autoimmune symptoms, including erythema nodosum, Raynaud's phenomenon, Sjogren syndrome, and refractory pruritus, having onset after 60-years of age. The inflammatory manifestations were largely refractory to traditional immunosuppressive regimens. Remarkably, treatment with a JAK-1 inhibitor, upadacitinib, in two cases yielded marked resolution of inflammatory symptoms, facilitating the gradual tapering of corticosteroids, improvement of hemoglobin levels, and reduction in serum C-reactive protein levels. Upon loss of response to upadacitinib, JAK-2 inhibitor ruxolitinib provided clinical benefit in one of the cases, facilitating further tapering of glucocorticoids. This arena warrants further exploration through prospective studies of larger cohorts to delineate optimal management strategies.</p></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"146 ","pages":"Article 107584"},"PeriodicalIF":2.1,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0145212624001504/pdfft?md5=274bd766483a1347ea587531359afb0f&pid=1-s2.0-S0145212624001504-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142145935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}